ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Price & Overview
NASDAQ:RARE • US90400D1081
The current stock price of RARE is 22.97 USD. Today RARE is up by 1.59%. In the past month the price decreased by -8.46%. In the past year, price decreased by -42.53%.
RARE Key Statistics
- Market Cap
- 2.22B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.84
- Dividend Yield
- N/A
RARE Stock Performance
RARE Stock Chart
RARE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to RARE. When comparing the yearly performance of all stocks, RARE is a bad performer in the overall market: 92.5% of all stocks are doing better.
RARE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RARE. Both the profitability and financial health of RARE have multiple concerns.
RARE Earnings
On February 12, 2026 RARE reported an EPS of -1.29 and a revenue of 207.00M. The company missed EPS expectations (-15.82% surprise) and beat revenue expectations (3.03% surprise).
RARE Forecast & Estimates
27 analysts have analysed RARE and the average price target is 57.68 USD. This implies a price increase of 151.11% is expected in the next year compared to the current price of 22.97.
For the next year, analysts expect an EPS growth of 24.05% and a revenue growth 13.01% for RARE
RARE Groups
Sector & Classification
RARE Financial Highlights
Over the last trailing twelve months RARE reported a non-GAAP Earnings per Share(EPS) of -5.84. The EPS increased by 7.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.53% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RARE Ownership
RARE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 402.17B | ||
| AMGN | AMGEN INC | 16.54 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.86 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.15 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.71 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.35 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.84 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.26 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 341.06 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RARE
Company Profile
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,371 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Company Info
IPO: 2014-01-31
ULTRAGENYX PHARMACEUTICAL IN
60 Leveroni Ct
Novato CALIFORNIA 94949 US
CEO: Emil D. Kakkis
Employees: 1371
Phone: 14154838800
ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ
What does ULTRAGENYX PHARMACEUTICAL IN do?
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,371 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Can you provide the latest stock price for ULTRAGENYX PHARMACEUTICAL IN?
The current stock price of RARE is 22.97 USD. The price increased by 1.59% in the last trading session.
Does ULTRAGENYX PHARMACEUTICAL IN pay dividends?
RARE does not pay a dividend.
How is the ChartMill rating for ULTRAGENYX PHARMACEUTICAL IN?
RARE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ULTRAGENYX PHARMACEUTICAL IN?
ULTRAGENYX PHARMACEUTICAL IN (RARE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for ULTRAGENYX PHARMACEUTICAL IN?
ULTRAGENYX PHARMACEUTICAL IN (RARE) currently has 1371 employees.
Can you provide the upcoming earnings date for ULTRAGENYX PHARMACEUTICAL IN?
ULTRAGENYX PHARMACEUTICAL IN (RARE) will report earnings on 2026-05-04.